By Mike Basset
Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more
More than 95% of BRCA1 or BRCA1 pathogenic variants would have been missed by DTC testing, largest such study showed
By Mark Fuerst
Direct-to-consumer (DTC) genetic testing has limited use as a screening tool for identifying individuals at risk of hereditary breast or ovarian cancer, especially in those of non-Ashkenazi Jewish descent, researchers reported.
Most current DTC genetic tests evaluate … Read more
The FDA has approved the first blood test that can help identify hundreds of potentially cancer-associated hereditary variants. The Invitae Common Hereditary Cancers Panel evaluates a blood sample to identify DNA variants in 47 genes associated with an elevated risk … Read more
By Hayden E. Klein
For Ovarian Cancer Awareness Month in September, Rebecca Brooks, MD, talked to The American Journal of Managed Care® (AJMC®) about how genetics and family history play a large role in ovarian cancer … Read more
Shared by Norma Rabago
When Juana Padron, a 40-year-old mother of four, chose to have a genetic test, going against her friends and family’s advice was the last thing on her mind.
Padron’s aunt died from breast cancer, and she … Read more
Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.
In an
by Jennifer Southall
Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.
The findings, presented at American Association … Read more
by Alison Kanski
NEW YORK – Personalized phone discussions about genetic risk assessment increased the number of breast and ovarian cancer patients who got genetic testing or discussed their risk with a genetic counselor, a study from Rutgers Cancer Institute … Read more
Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
by Mark L. Fuerst
Most people with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and the majority have not had genetic testing.
In a recent article in the ASCO Educational Book, Melissa Frey, MD, MS, … Read more
by Cedars-Sinai
New Studies Led by Cedars-Sinai Investigators Help Pinpoint Genetic Risk Factors Tied to Increased Risk of Ovarian Cancer and Suggest How to Better Identify Women Most At Risk
Image on left: Simon Gayther, PhD, professor of Biomedical Sciences, … Read more
by Erin Hunter
Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.
A new study shows that access to clinician
Reviewed by Emily Henderson, B.Sc.
JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that … Read more
by Caren Begun
Tennis legend Chris Evert—known for her 18-time grand slam success in the sport—has made recent headlines after revealing an early-stage ovarian cancer diagnosis and speaking out to help others by sharing her personal experience.
According to the … Read more
by M. Alexander Otto, MMS, PA
Despite unequivocal recommendations for universal germline BRCA testing in women with ovarian cancer, an analysis of a large commercial insurance database between 2008 and 2018 found that only about one third (33.9%) of such … Read more
by Sophia George
Providing equal access to care will not by itself equalize outcomes between Black and white women.
Women from the African diaspora are disproportionately affected by high-grade and aggressive ovarian tumours. In the United States, mortality due to … Read more
by Alison Kanski
NEW YORK – Gynecologic oncology fellows at Memorial Sloan Kettering have developed an online resource for cancer patients, family members, and doctors aiming to raise awareness of genetic cancer risks and spur more testing among relatives for … Read more
By Krista Conger
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Women newly diagnosed with breast or ovarian cancer who are also … Read more
Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1… Read more
By Christina Bennett, MS
The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results … Read more
